RB is the world's leading consumer health and hygiene company. It's tried and tested, we challenge it. We continually invest in research and innovation to stay ahead of the game. In fact, we are changing the game in consumer health, working with people to challenge conventional thinking - whether it is product, packaging and delivery, consumer information or marketing. That's how we keep generating the breakthrough thinking and ideas that built 19 iconic Powerbrands around the world.
Raptor Pharmaceutical Corp., a biopharmaceutical company developing and commercializing transformative treatments for rare diseases, presented results from a network meta-analysis comparing inhaled antibiotics for cystic fibrosis (CF) patients with lung infections involving Pseudomonas aeruginosa. The study showed that Quinsair, a levofloxacin inhalation solution, had efficacy comparable to three other inhalable antibiotics also approved for use in Europe. These data were presented at the European Respiratory Society (ERS) International Congress 2016 in London.
[adsense:336x280:8701650588]

